Bavarian Nordic (OTCMKTS:BVNRY) is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.
The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis. These vaccines are produced at Bavarian Nordic’s GMP-certified facility in Kvistgård, Denmark, which has capacity for both clinical and large-scale commercial production.
In addition to its marketed products, Bavarian Nordic maintains a pipeline of novel immunotherapies and combination approaches in oncology. Key clinical candidates include cancer vaccines targeting tumor-associated antigens, as well as next-generation constructs designed to enhance T-cell responses. The company has established research collaborations and licensing agreements with leading pharmaceutical firms and academic institutions to advance its technology platforms into new therapeutic areas.
Bavarian Nordic serves markets across North America, Europe and select international territories, supported by a global commercial infrastructure and strategic partnerships. Under the leadership of Chief Executive Officer Paul Chaplin, the company continues to expand its product offerings, strengthen its manufacturing capabilities and explore new applications for its viral vector expertise in the pursuit of novel prevention and treatment solutions.
